Trial Profile
A Double Blind, Randomized, Placebo-controlled, Single Center, Phase 2a Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 463588 Administered Subcutaneously Once Weekly for 13 Weeks in Obese Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs IONIS-FGFR4Rx (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms FGFR4-CS2
- Sponsors Ionis Pharmaceuticals
- 06 Feb 2017 Status changed from active, no longer recruiting to completed.
- 06 Feb 2017 Status changed from active, no longer recruiting to completed.
- 17 Oct 2016 Status changed from recruiting to active, no longer recruiting.